EXCIVA TARGETEDDRUGRESCUE - Trademark Details![Image for trademark with serial number 87695736](/media/image.php?serial=87695736)
Status: 700 - Registered
Serial Number
87695736
Registration Number
5667395
Word Mark
EXCIVA TARGETEDDRUGRESCUE
Status
700 - Registered
Status Date
2019-01-29
Filing Date
2017-11-22
Registration Number
5667395
Registration Date
2019-01-29
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s)
Typeset
Design Searches
261709 - Curved line(s), band(s) or bar(s).
Published for Opposition Date
2018-04-10
Attorney Name
Law Office Assigned Location Code
L90
Employee Name
ROSSMAN, WILLIAM M
Statements
Indication of Colors claimed
The color(s) Turquoise blue and royal blue is/are claimed as a feature of the mark.
Description of Mark
The mark consists of The trademark is the logo of the company comprising a turquoise blue crescent, royal blue "exciva", turquoise blue "TARGETED", royal blue "DRUG", turquoise blue "RESCUE", and two royal blue curved wings above and below the text.
Goods and Services
Allergy medications; Amino acid preparations for medical purposes; Antiallergic medicines; Cardiovascular agents for medical purposes; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Dietary and nutritional supplements; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Nutraceuticals for use as a dietary supplement; Nutritional supplements; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders
Pseudo Mark
EXCIVA TARGETED DRUG RESCUE
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2017-12-05
Primary Code
005
First Use Anywhere Date
2018-07-02
First Use In Commerce Date
2018-07-02
Current Trademark Owners
Party Name
Party Type
31 - 1st New Owner Entered After Registration
Legal Entity Type
27
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Party Type
31 - 1st New Owner Entered After Registration
Legal Entity Type
27
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
30 - Original Registrant
Legal Entity Type
16 - Limited Liability Company
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
16 - Limited Liability Company
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
16 - Limited Liability Company
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Sreenivasarao Vepachedu
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2017-11-25 | NEW APPLICATION ENTERED IN TRAM |
2017-12-05 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2017-12-06 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
2018-03-07 | ASSIGNED TO EXAMINER |
2018-03-07 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2018-03-21 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2018-04-03 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
2018-04-03 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
2018-04-10 | PUBLISHED FOR OPPOSITION |
2018-04-10 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2018-06-05 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2018-11-14 | TEAS STATEMENT OF USE RECEIVED |
2018-12-01 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2018-11-14 | USE AMENDMENT FILED |
2018-12-01 | STATEMENT OF USE PROCESSING COMPLETE |
2018-12-25 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
2018-12-26 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
2019-01-29 | REGISTERED-PRINCIPAL REGISTER |
2019-08-07 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
2020-03-08 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
2020-03-08 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
2020-03-08 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
2020-03-08 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
2020-03-08 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
2020-03-08 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
2020-05-13 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
2020-06-11 | REVIEW OF CORRESPONDENCE COMPLETE - INFORMATION MADE OF RECORD |
2020-07-04 | TEAS SECTION 7 REQUEST RECEIVED |
2020-11-03 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
2020-11-04 | POST REGISTRATION ACTION MAILED - SEC. 7 |